Trade Cassava Sciences Inc - SAVA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.59 |
| Open | 1.57 |
| 1-Year Change | -92.35% |
| Day's Range | 1.54 - 1.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.59 | 0.02 | 1.27% | 1.57 | 1.63 | 1.53 |
| Apr 23, 2025 | 1.59 | 0.01 | 0.63% | 1.58 | 1.66 | 1.51 |
| Apr 22, 2025 | 1.52 | 0.17 | 12.59% | 1.35 | 1.54 | 1.35 |
| Apr 21, 2025 | 1.40 | -0.03 | -2.10% | 1.43 | 1.43 | 1.31 |
| Apr 17, 2025 | 1.38 | 0.04 | 2.99% | 1.34 | 1.47 | 1.34 |
| Apr 16, 2025 | 1.36 | 0.01 | 0.74% | 1.35 | 1.36 | 1.31 |
| Apr 15, 2025 | 1.36 | 0.09 | 7.09% | 1.27 | 1.40 | 1.23 |
| Apr 14, 2025 | 1.27 | 0.01 | 0.79% | 1.26 | 1.33 | 1.22 |
| Apr 11, 2025 | 1.22 | 0.07 | 6.09% | 1.15 | 1.23 | 1.14 |
| Apr 10, 2025 | 1.12 | -0.03 | -2.61% | 1.15 | 1.17 | 1.09 |
| Apr 9, 2025 | 1.17 | 0.02 | 1.74% | 1.15 | 1.25 | 1.09 |
| Apr 8, 2025 | 1.14 | -0.10 | -8.06% | 1.24 | 1.29 | 1.14 |
| Apr 7, 2025 | 1.26 | 0.13 | 11.50% | 1.13 | 1.37 | 1.13 |
| Apr 4, 2025 | 1.24 | 0.09 | 7.83% | 1.15 | 1.24 | 1.11 |
| Apr 3, 2025 | 1.20 | -0.07 | -5.51% | 1.27 | 1.31 | 1.19 |
| Apr 2, 2025 | 1.32 | 0.02 | 1.54% | 1.30 | 1.35 | 1.28 |
| Apr 1, 2025 | 1.31 | -0.12 | -8.39% | 1.43 | 1.43 | 1.29 |
| Mar 31, 2025 | 1.44 | -0.09 | -5.88% | 1.53 | 1.57 | 1.44 |
| Mar 28, 2025 | 1.61 | -0.05 | -3.01% | 1.66 | 1.72 | 1.57 |
| Mar 27, 2025 | 1.65 | 0.01 | 0.61% | 1.64 | 1.68 | 1.58 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cassava Sciences Inc. Company profile
Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.
According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis.
Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.
SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.
Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.
| Industry: | Bio Therapeutic Drugs |
6801 N Capital Of Texas Highway
Building 1; Suite 300
AUSTIN
TEXAS 78731
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com